In the original article, the SCN panel for “Hep G2 cells” in Figure 2B was inadvertently wrongly provided. The corrected image of the SCN panel for “Hep G2 cells” with data in Figure 2B is provided below. The related data description of Figure 2B on page 926, left column, is also corrected to clarify the presentations. These corrections do not affect the main conclusions of this paper. We apologize for any inconvenience and misunderstanding caused by these errors. When cells were treated with 1.57 μM sorafenib and 5.43 μM curcumin, the induced apoptosis percentages by sorafenib, curcumin, Sora + Cur, and SCN were 25.64%, 22.05%, 22.05%, and 56.22% in BEL-7402 cells, and 18.59%, 25.7%, 24.63%, and 50.66% in Hep G2 cells, respectively.

Figure 2

Figure 2. Mitochondrial membrane potential (MMP) and cell apoptosis in BEL-7402 cells and Hep G2 cells treated with sorafenib, curcumin, Sora + Cur, and SCN with 1.57 μM sorafenib and 5.43 μM curcumin. (A) Relative MMP values, *p < 0.05; (B) cell percentages at early apoptotic and late apoptotic stages in BEL-7402 cells (48 h of incubation) and Hep G2 cells (24 h of incubation) upon each treatment.

High Resolution Image

Download MS PowerPoint Slide

Compared with free sorafenib and curcumin monotherapy, the apoptotic cell percentages were not significantly changed by Sora + Cur, but obviously enhanced by SCN. Typically, SCN treatment, respectively, resulted in an enhancement of 2.19 and 2.55 times in BEL-7402 cells and 2.73- and 1.97-fold in Hep G2 cells over free sorafenib and curcumin monotherapy. Moreover, the induced cell apoptosis in BEL-7402 cells and Hep G2 cells by SCN was, respectively, 2.55- and 2.06-fold of Sora + Cur, which clearly verified the significant enhancement of cell apoptosis by coassembled nanoparticles of SCN. Figure 2. Mitochondrial membrane potential (MMP) and cell apoptosis in BEL-7402 cells and Hep G2 cells treated with sorafenib, curcumin, Sora + Cur, and SCN with 1.57 μM sorafenib and 5.43 μM curcumin. (A) Relative MMP values, *p < 0.05; (B) cell percentages at early apoptotic and late apoptotic stages in BEL-7402 cells (48 h of incubation) and Hep G2 cells (24 h of incubation) upon each treatment. This article has not yet been cited by other publications. Figure 2. Mitochondrial membrane potential (MMP) and cell apoptosis in BEL-7402 cells and Hep G2 cells treated with sorafenib, curcumin, Sora + Cur, and SCN with 1.57 μM sorafenib and 5.43 μM curcumin. (A) Relative MMP values, *p < 0.05; (B) cell percentages at early apoptotic and late apoptotic stages in BEL-7402 cells (48 h of incubation) and Hep G2 cells (24 h of incubation) upon each treatment.

中文翻译：

---

定向自组装纳米粒子对索拉非尼和姜黄素的代码传递的校正增强了对肝细胞癌的治疗效果。

在原始文章中，错误地提供了图2B中“ Hep G2细胞”的SCN面板。下面提供了图2B中“ Hep G2细胞”的SCN面板的校正图像。在第926页左栏的图2B的相关数据描述也已更正，以阐明显示内容。这些更正不会影响本文的主要结论。对于这些错误给您带来的任何不便和误解，我们深表歉意。当用1.57μM索拉非尼和5.43μM姜黄素处理细胞时，索拉非尼，姜黄素，Sora + Cur和SCN在BEL-7402细胞中诱导的凋亡百分比分别为25.64％，22.05％，22.05％和56.22％，以及18.59％。在Hep G2细胞中分别为25.7％，24.63％和50.66％。

图2

图2.用索拉非尼，姜黄素，Sora + Cur和SCN用1.57μM索拉非尼和5.43μM姜黄素处理的BEL-7402细胞和Hep G2细胞中的线粒体膜电位（MMP）和细胞凋亡。（A）相对MMP值* p <0.05；（B）每次处理后，BEL-7402细胞（培养48小时）和Hep G2细胞（培养24小时）在凋亡早期和凋亡晚期的细胞百分比。

高分辨率图像

下载MS PowerPoint幻灯片

与游离索拉非尼和姜黄素单药治疗相比，Sora + Cur的凋亡细胞百分比无明显变化，但SCN明显增加。通常，与游离索拉非尼和姜黄素单药治疗相比，SCN处理分别使BEL-7402细胞的增殖能力提高2.19倍和2.55倍，使Hep G2细胞的增殖能力提高2.73倍和1.97倍。此外，SCN诱导的BEL-7402细胞和Hep G2细胞的细胞凋亡分别是Sora + Cur的2.55倍和2.06倍，这清楚地证明了SCN的共组装纳米颗粒显着增强了细胞凋亡。图2.用索拉非尼，姜黄素，Sora + Cur和SCN用1.57μM索拉非尼和5.43μM姜黄素处理的BEL-7402细胞和Hep G2细胞中的线粒体膜电位（MMP）和细胞凋亡。（A）相对MMP值* p<0.05；（B）每次处理后BEL-7402细胞（培养48小时）和Hep G2细胞（培养24小时）早期凋亡阶段和晚期凋亡阶段的细胞百分比。本文尚未被其他出版物引用。图2.用索拉非尼，姜黄素，Sora + Cur和SCN用1.57μM索拉非尼和5.43μM姜黄素处理的BEL-7402细胞和Hep G2细胞中的线粒体膜电位（MMP）和细胞凋亡。（A）相对MMP值* p <0.05；（B）每次处理后BEL-7402细胞（培养48小时）和Hep G2细胞（培养24小时）早期凋亡阶段和晚期凋亡阶段的细胞百分比。